Matthew C. Garrett Sells 42,910 Shares of Irhythm Technologies Inc (IRTC) Stock

Irhythm Technologies Inc (NASDAQ:IRTC) CFO Matthew C. Garrett sold 42,910 shares of the company’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $59.17, for a total transaction of $2,538,984.70. Following the completion of the transaction, the chief financial officer now owns 36,085 shares in the company, valued at $2,135,149.45. The transaction was disclosed in a filing with the SEC, which is available at this link.

Irhythm Technologies Inc (IRTC) opened at $60.04 on Thursday. The firm has a market cap of $1,390.00 and a PE ratio of -50.45. Irhythm Technologies Inc has a 1-year low of $28.70 and a 1-year high of $60.81. The company has a current ratio of 7.65, a quick ratio of 7.57 and a debt-to-equity ratio of 0.38.

Irhythm Technologies (NASDAQ:IRTC) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.05. The business had revenue of $25.04 million for the quarter, compared to analyst estimates of $24.30 million. Irhythm Technologies had a negative net margin of 27.56% and a negative return on equity of 27.67%. The company’s revenue was up 49.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.80) EPS. research analysts anticipate that Irhythm Technologies Inc will post -1.17 earnings per share for the current year.

Several research analysts have recently weighed in on the stock. BidaskClub lowered shares of Irhythm Technologies from a “hold” rating to a “sell” rating in a report on Thursday, December 14th. Zacks Investment Research lowered shares of Irhythm Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Dougherty & Co assumed coverage on shares of Irhythm Technologies in a report on Friday, December 1st. They set a “neutral” rating on the stock. Canaccord Genuity increased their price objective on shares of Irhythm Technologies from $55.00 to $59.00 and gave the stock a “buy” rating in a report on Thursday, November 2nd. Finally, ValuEngine upgraded shares of Irhythm Technologies from a “sell” rating to a “hold” rating in a report on Saturday, October 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $65.25.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc increased its position in Irhythm Technologies by 131.0% during the 2nd quarter. Legal & General Group Plc now owns 3,373 shares of the company’s stock worth $143,000 after purchasing an additional 1,913 shares in the last quarter. Advisor Group Inc. increased its position in Irhythm Technologies by 763.9% during the 3rd quarter. Advisor Group Inc. now owns 2,920 shares of the company’s stock worth $151,000 after purchasing an additional 2,582 shares in the last quarter. Voya Investment Management LLC acquired a new stake in Irhythm Technologies during the 2nd quarter worth approximately $274,000. GSA Capital Partners LLP acquired a new stake in Irhythm Technologies during the 2nd quarter worth approximately $289,000. Finally, Nationwide Fund Advisors increased its position in Irhythm Technologies by 92.8% during the 2nd quarter. Nationwide Fund Advisors now owns 7,843 shares of the company’s stock worth $333,000 after purchasing an additional 3,774 shares in the last quarter. 97.80% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2018/01/11/matthew-c-garrett-sells-42910-shares-of-irhythm-technologies-inc-irtc-stock.html.

About Irhythm Technologies

iRhythm Technologies, Inc is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report.

Insider Buying and Selling by Quarter for Irhythm Technologies (NASDAQ:IRTC)

Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit